Humanigen Inc (HGENQ)

[Citrati]

Not trying to be difficult here, just trying to make sure I understand everything.
According to the Aug 10, 10Q the operating loss for the last 6 months was $15,662,000. If that holds true for the rest of 2015 then a huge portion of their cash and equivalents will be used by January. This assumes no increase in trial costs, R&D or general administrative expenses. Since it is always best to raise money before needed, it would seem logical for them to do a capital raise in the next 3-6 months or at least file an S-3.
Are there any grants or partnership considerations on the horizon that could mitigate the amount needed?
Since there agreement with Sanofi was terminated and work on the KB001-A suspended;
" Based on results of the Phase 2 data released in early 2015, we have discontinued development of KB001-A in all indications." ; I assume there will be no further funding/licensing or agreements with Sanofi.
Since trial phases run into the tens of millions and succeeding trials usually increase in cost I am also concluding the need for further capital infusion.

Take into consideration my dd is not complete. Please correct, add to and/or point me to other facts to round out the picture.

Thanks. IMO it looks like an early stage bio with a lot of promise and upside.
KBIO